«It's the same technology WRAIR has used to successfully develop other
flavivirus vaccines.»
Not exact matches
«In addition, this platform can be used to develop safe
vaccine candidates for other
flaviviruses such as Zika virus, where pregnant women are the target group for vaccination.»
WRAIR is moving forward with the purified inactivated virus (PIV)
vaccine, called ZPIV, because it builds on «a type of
vaccine that has been licensed before,» said Col. Stephen Thomas, an infectious disease Army physician and a vaccinologist specializing in
flaviviruses, and the WRAIR Zika program lead.
«The study indicates that prior
flavivirus immunity is unlikely to impact the safety of a Zika
vaccine candidate.
All the viruses except the yellow fever
vaccine offered protection: Hamsters pre-exposed to another
flavivirus held the West Nile virus in check and survived, whereas those in a control group got sick and about half died after 10 days.
«The Army was able to move so quickly in developing, manufacturing and testing a Zika
vaccine because of its extensive experience with this
vaccine platform and long standing investments in the understanding and mitigation of
flaviviruses, like yellow fever, dating back to the founding of WRAIR,» said Dr. Kayvon Modjarrad, Zika program co-lead and associate director for Emerging Infectious Disease Threats at WRAIR's MHRP.